Macroscopic fluctuation theory of interacting Brownian particles

Number of Local Minima in Discrete-Time Fractional Brownian Motion

Universal Scale-Free Decay of Tracer-Bath Correlations in d-Dimensional Interacting Particle Systems

Exact Large-Scale Correlations in Diffusive Systems with General Interactions

Tracer and Current Fluctuations in Driven Diffusive Systems

Visitation Dynamics of d-Dimensional Fractional Brownian Motion

From Maximum of Inter-Visit Times to Starving Random Walks

Semi-infinite Simple Exclusion Process: From Current Fluctuations to Target Survival

Full-record statistics of one-dimensional random walks

Tracer Diffusion beyond Gaussian Behavior: Explicit Results for General Single-File Systems

From Particle Currents to Tracer Diffusion: Universal Correlation Profiles in Single-File Dynamics

Absolute Negative Mobility of an Active Tracer in a Crowded Environment

Exact spatial correlations in single-file diffusion

Driven Tracer in the Symmetric Exclusion Process: Linear Response and Beyond

Complete visitation statistics of one-dimensional random walks

Path integrals for fractional Brownian motion and fractional Gaussian noise

Exact time dependence of the cumulants of a tracer position in a dense lattice gas

Microscopic Theory for the Diffusion of an Active Particle in a Crowded Environment

Generalized Correlation Profiles in Single-File Systems

Pair correlation of dilute active Brownian particles: From low-activity dipolar correction to high-activity algebraic depletion wings

Universality Classes of Hitting Probabilities of Jump Processes

Cumulant generating functions of a tracer in quenched dense symmetric exclusion processes

Reply to "Comment on 'Inverse Square Lévy Walks are not Optimal Search Strategies for d≥2"'

Equilibrium properties of two-species reactive lattice gases on random catalytic chains

Inverse Square Lévy Walks are not Optimal Search Strategies for d≥2

Optimized Diffusion of Run-and-Tumble Particles in Crowded Environments

N-tag probability law of the symmetric exclusion process

Nonequilibrium Fluctuations and Enhanced Diffusion of a Driven Particle in a Dense Environment

Unbinding Transition of Probes in Single-File Systems

Universal Long Ranged Correlations in Driven Binary Mixtures

Optimal search strategies of run-and-tumble walks

Temporal Correlations of the Running Maximum of a Brownian Trajectory

Rationale for Strengthening Muscle to Prevent Falls and Fractures: A Review of the Evidence

Contact Kinetics in Fractal Macromolecules

Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial

Evidence and quantification of memory effects in competitive first-passage events

Record ages of non-Markovian scale-invariant random walks

Universal exploration dynamics of random walks

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist

Exact closure and solution for spatial correlations in single-file diffusion

Universal kinetics of imperfect reactions in confinement

Cell migration guided by long-lived spatial memory

Superionic liquids in conducting nanoslits: A variety of phase transitions and ensuing charging behavior

Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

A Phase 2 Randomized Study Investigating the Efficacy and Safety of Myostatin Antibody LY2495655 versus Placebo in Patients Undergoing Elective Total Hip Arthroplasty

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a BTLA Agonist Antibody (Venanprubart) in Healthy Participants, Patients with Systemic Lupus Erythematosus, and Patients with Psoriasis: Results From Three Phase 1 Studies

A Phase 2 Randomized Study Investigating the Efficacy and Safety of Myostatin Antibody LY2495655 versus Placebo in Patients Undergoing Elective Total Hip Arthroplasty

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity